Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Total Assets

Last Annual Value

563.83M

3-Year CAGR

177%

5-Year CAGR

54%

10-Year CAGR

53%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Total Assets

SLNO · NASDAQ
CompanyTotal Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
563.83M
46.1%73.8%58.7% 
1.53B
0.9%0.1%11.0%
1.19B
93.0%22.8%-21.3%
CELC logo
Celcuity Inc.
NASDAQ:CELC
466.56M
34.6%40.3%54.4%
937.91M
120.1%26.2%N/A
715.73M
24.8%27.7%47.6%
937.13M
32.7%N/AN/A
842.81M
9.2%23.4%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01